VC-backed Cortexyme goes public
South San Francisco-based Cortexyme Inc, a developer of drugs focused on treating Alzheimer’s disease and other degenerative diseases, has debuted its IPO after pricing its over 4.4 million shares at $17 per share. The stock began trading May 9, 2019 on the NASDAQ under the ticker symbol "CRTX." BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are the lead underwriters. Cortexyme's pre-IPO backers included Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capital Group, RSL Investments, Huizenga Capital, Pfizer, Takeda Ventures, Lamond Family, Breakout Ventures and Dolby Family Ventures.
9 May 2019•3 mins read
